Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEli Lilly and Company

Eli Lilly and Company

Healthcare Drug Manufacturers - General
PortfolioPortfolio WatchlistWatchlist
Company price
1409.39 USD -1.60 ( 0.11%)
Last update at 2026-11-03T21:00:00Z
VOLUME
1860698
Market Cap
1013116.31M
P/E
38.16

Momentum Score

…

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1393.47
Low
1437.00
High
52 Week Price Range
707.59
Low
1292.65
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Eli Lilly is a global pharmaceutical company developing and commercializing medicines for diabetes, obesity, oncology, neuroscience and immunology. Long-term growth may be supported by GLP-1 and dual-agonist diabetes/weight-loss therapies, a diversified oncology and neuroscience pipeline, and an established global commercial footprint. The company appears positioned to translate R&D and strong cash generation into sustained product launches.
Key risks include intense competition in metabolic therapies, regulatory and clinical trial outcomes for pipeline candidates, patent expirations and pricing or reimbursement pressures.

Risk Score
Low

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1410.99
Dividend Yield
0.57%
Revenue TTM
79666.00M
Revenue Per Share
89.02
Gross Profit TTM
66441.00M
Debt / Equity
1.60
ROE
102.29%
Net Debt
35340.00M
ROCE
34.14%
Diluted EPS TTM
29.77

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 25729.90M 12680.40M 6554.60M 6806.40M 6155.50M
Net income 20638.30M 10590.00M 5240.40M 6244.80M 5581.70M
Selling general administrative 11094.00M 8132.10M 6941.20M 6440.40M 6431.60M
Selling and marketing expenses - - 461.90M - -
Gross profit 54615.00M 36624.40M 27041.90M 21911.60M 21005.60M
Reconciled depreciation 1997.00M 1766.60M 1527.30M 1522.50M 1547.60M
Ebit 26373.00M 13461.00M 7040.50M 7127.30M 6357.10M
Ebitda 27936.50M 15227.60M 8567.80M 9433.50M 8739.10M
Depreciation and amortization 1563.50M 1766.60M 1527.30M 2306.20M 2382.00M
Non operating income net other - - - -320.90M -
Operating income 29696.00M 17501.70M 10787.30M 7127.30M 6357.10M
Other operating expenses 35483.00M 27541.00M 23336.80M 20261.00M 20770.30M
Interest expense 795.30M 780.60M 485.90M 331.60M 339.80M
Tax provision 5091.00M 2090.40M 1314.20M 561.60M 573.80M
Interest income 642.00M 175.20M 173.60M 268.80M 314.40M
Net interest income - -605.40M -312.30M -268.80M -314.40M
Extraordinary items - - - - 0.00M
Non recurring - - - 244.60M -
Income tax expense 5091.60M 2090.40M 1314.20M 561.60M 573.80M
Total revenue 65179.00M 45042.70M 34124.10M 28541.40M 28318.40M
Total operating expenses 24919.00M 19122.70M 16254.60M 13631.20M 13457.50M
Cost of revenue 10564.00M 8418.30M 7082.20M 6629.80M 7312.80M
Total other income expense net -3965.00M -4821.30M -4232.70M -320.90M -201.60M
Net income from continuing ops 20640.00M 10590.00M 5240.40M 6244.80M 5581.70M
Net income applicable to common shares 20640.00M 10590.00M 5240.40M 6244.80M 5581.70M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 112476.00M 78714.90M 64006.30M 49489.80M 48806.00M
Intangible assets 6521.00M 6166.30M 6906.60M 7206.60M 7691.90M
Other current assets 14462.00M 8451.90M 5690.30M 2954.10M 2530.60M
Total liab 85941.00M 64443.30M 53142.60M 38714.40M 39651.20M
Total stockholder equity 26535.00M 14192.10M 10771.90M 10649.80M 8979.20M
Deferred long term liab - - - 87.30M -
Other current liab 22339.00M 20030.90M 13940.70M 13706.50M 3027.50M
Common stock 590.00M 592.40M 593.60M 594.10M 596.30M
Capital stock 590.00M 592.40M 593.60M 594.10M 596.30M
Retained earnings 24470.00M 13545.00M 10312.30M 10042.60M 8958.50M
Other liab - - - 6130.40M 8674.20M
Good will 5898.00M 5770.30M 4939.70M 4073.00M 3892.00M
Other assets 15691.00M 29221.30M - 7129.90M 6380.00M
Cash 7163.00M 3268.40M 2818.60M 2067.00M 3818.50M
Cash and equivalents 7268.00M 3268.40M - 2067.00M 3818.50M
Total current liabilities 35228.00M 28376.60M 27293.20M 17138.20M 15052.70M
Current deferred revenue - - 14508.60M - 8816.30M
Net debt 35340.00M 30375.80M 22406.70M 14171.60M 13066.20M
Short term debt 1635.00M 5117.10M 6904.50M 1501.10M 1538.30M
Short long term debt 1635.00M 5117.10M 6904.50M 1501.10M 1538.30M
Short long term debt total 42503.00M 33644.20M 25225.30M 16238.60M 16884.70M
Other stockholder equity 4355.00M 4376.60M 4193.00M 3857.70M 3767.50M
Property plant equipment 25935.00M 17102.40M - 10144.00M 8985.10M
Total current assets 55629.00M 32739.70M 25727.00M 18034.50M 18452.40M
Long term investments 2802.00M 3215.90M 3052.20M 2901.80M 3212.60M
Net tangible assets - - - -629.80M -4014.80M
Short term investments 105.00M 154.80M 109.10M 144.80M 90.10M
Net receivables 20155.00M 13275.40M 11336.20M 8558.90M 8127.20M
Long term debt 40868.00M 28527.10M 18320.80M 14737.50M 15346.40M
Inventory 13744.00M 7589.20M 5772.80M 4309.70M 3886.00M
Accounts payable 5379.00M 3228.60M 2598.80M 1930.60M 1670.60M
Noncontrolling interest in consolidated entity - - 91.80M 125.60M -
Accumulated other comprehensive income -2880.00M -4321.90M -4327.00M -3844.60M -4343.10M
Additional paid in capital - - 7250.40M - -
Common stock total equity - - - 594.10M -
Retained earnings total equity - - - 10042.60M -
Treasury stock - - -44.20M - -52.70M
Non currrent assets other 6992.00M 5719.70M 4989.90M 4337.00M 4082.70M
Non current assets total 56847.00M 45975.20M 38279.30M 31455.30M 30353.60M
Long term debt total 40868.00M 28527.10M - 14737.50M 15346.40M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 319.00M -9301.50M -7152.70M -244.00M -166.00M
Change to liabilities - - - 1678.30M -664.10M
Total cashflows from investing activities -10972.00M -9301.50M -7152.70M -3762.90M -2867.50M
Net borrowings 8051.00M 8901.10M - -62.00M 501.40M
Total cash from financing activities -2213.00M 1230.10M 3495.60M -5406.70M -4131.30M
Change to operating activities - - - -793.50M 1515.40M
Net income 20640.00M 10590.00M 5240.40M 6244.80M 5581.70M
Change in cash 4000.00M 449.80M 751.60M -1751.50M 161.40M
Begin period cash flow 3268.00M 2818.60M 2067.00M 3818.50M 3657.10M
End period cash flow 7268.00M 3268.40M 2818.60M 2067.00M 3818.50M
Total cash from operating activities 16813.00M 8817.90M 4240.10M 7084.40M 7260.70M
Depreciation 1997.00M 1766.60M 1527.30M 1522.50M 1547.60M
Other cashflows from investing activities -2789.00M -3042.70M -2532.10M -1163.30M 24.30M
Dividends paid 5384.00M 4680.40M 4069.30M 3535.80M 3086.80M
Change to inventory -4671.00M -2507.40M -1425.00M -599.70M -235.90M
Change to account receivables -7000.00M -2155.20M -2451.00M -299.60M -1278.30M
Sale purchase of stock -4108.00M -2500.00M -750.00M -1500.00M -1250.00M
Other cashflows from financing activities -772.00M -490.60M -335.00M 1189.10M -295.90M
Change to netincome - - - -668.40M 1154.00M
Capital expenditures 7841.00M 8403.60M 7392.10M 2484.00M 1873.20M
Change receivables - - - -299.60M -
Cash flows other operating - - - -793.50M -
Cash and cash equivalents changes - - - -1583.90M -
Change in working capital -8093.00M -5385.00M -3055.00M -14.50M -1022.60M
Stock based compensation 626.00M 645.60M 628.50M 371.10M 342.80M
Other non cash items 3350.00M 3883.80M 2239.90M 1145.70M 1613.50M
Free cash flow 8972.00M 414.30M -3152.00M 4600.40M 5387.50M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - General

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
LLY
Eli Lilly and Company		 -1.60
0.11%		 1409.39 38.16 24.15 12.72 29.95 13.31 25.43
JNJ
Johnson & Johnson		 -4.40
1.63%		 266.16 30.96 20.79 6.58 7.55 6.84 19.73
ABBV
AbbVie Inc		 -2.84
0.98%		 286.00 74.10 16.21 7.22 50.46 8.18 27.04
RHHVF
Roche Holding AG Participation		 -10.00
2.06%		 475.00 24.16 16.53 5.71 8.88 4.94 14.76
RHHBY
Roche Holding Ltd ADR		 -1.51
2.49%		 59.17 23.48 16.31 5.56 8.78 4.94 14.76

Profile*

Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Lilly Corporate Center, Indianapolis, IN, United States, 46285

317 276 2000

https://www.lilly.com

50000

Name Title Year Born
Mr. David A. Ricks Chairman, CEO & Pres 1968
Ms. Anat Ashkenazi Sr. VP & CFO 1972
Dr. Daniel M. Skovronsky M.D., Ph.D. Sr. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Labs 1974
Mr. Diogo Rau Sr. VP & Chief Information and Digital Officer NA
Mr. Jacob S. Van Naarden Sr. VP, CEO of Loxo Oncology & Pres of Lilly Oncology 1985
Mr. Donald A. Zakrowski Chief Accounting Officer & VP of Fin. NA
Mr. Martin Bott MIBS VP of Fin. & Special Projects 1963
Ms. Anat Hakim J.D. Sr. VP, Gen. Counsel & Sec. 1969
Mr. Alonzo Weems Sr. VP and Chief Ethics & Compliance Officer NA
Ms. Leigh Ann Pusey Sr. VP of Corp. Affairs & Communications 1963

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…